INVESTORS & MEDIA

Corporate Governance

Corporate Governance

Date Name Title Type Shares Traded Price
Dec 15, 2003
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Grant, award or other acquisition pursuant to Rule 16b-3(d) 192,308 --
Feb 11, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 189,463 $9.49
Feb 11, 2014
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 189,463 --
Dec 15, 2004
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Grant, award or other acquisition pursuant to Rule 16b-3(d) 189,463 --
Jun 17, 2004
Director
Director Other acquisition or disposition (describe transaction) 189,345 --
Jun 17, 2004
Director
Director Other acquisition or disposition (describe transaction) 189,345 --
May 11, 2020
Director, President & CEO
Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 187,500 $30.63
May 11, 2020
Director, President & CEO
Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 187,500 --
Dec 12, 2019
Director, President & CEO
Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 187,500 $21.25
Dec 12, 2019
Director, President & CEO
Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 187,500 --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

IR Tools